Cryoport's debt levels appear manageable, given healthy cash reserves and short-term assets. However, meeting future obligations will hinge on its profitability, an area where the company's performance has faltered. Cryoport saw modest revenue growth and a cash outflow last year.
Cryoport股票讨论
VGXI选择Cryoport提供生物储存、生物服务和供应链解决方案,以推进下一代疗法
Cryoport公司(纳斯达克:CYRX)和VGXI公司宣布建立战略合作伙伴关系,支持生物制药公司开发细胞和基因疗法以及mRNA治疗。合作将于2024年10月开始,Cryoport系统将从位于得克萨斯州休斯敦的设施为VGXI在伍兹兰和康罗得克萨斯州设施制造的质粒DNA产品提供生物储存和生物服务。
暂无评论